3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine

Last updated
3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine
FLEA.svg
Clinical data
Other names3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine; 3,4-Methylenedioxy-N-methyl-N-hydroxyamphetamine; MDMOH; MDHMA; N-Hydroxy-MDMA; FLEA
Legal status
Legal status
Identifiers
  • 1-(1,3-Benzodioxol-5-yl)-N-hydroxy-N-methylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
Formula C11H15NO3
Molar mass 209.245 g·mol−1
3D model (JSmol)
  • C1=C2C(=CC=C1CC(C)N(C)O)OCO2
  • InChI=1S/C11H15NO3/c1-8(12(2)13)5-9-3-4-10-11(6-9)15-7-14-10/h3-4,6,8,13H,5,7H2,1-2H3
  • Key:ORADFQZOLNHWRQ-UHFFFAOYSA-N

3,4-Methylenedioxy-N-hydroxy-N-methylamphetamine, also known as MDMOH, MDHMA, or FLEA, is an entactogen, psychedelic, and stimulant of the phenethylamine, amphetamine, and MDxx families. It is the N-hydroxy homologue of MDMA ("Ecstasy"), and the N-methyl homologue of MDOH. FLEA was first synthesized and assayed by Alexander Shulgin. [1] In his book PiHKAL (Phenethylamines i Have Known And Loved), Shulgin listed the dosage range as 100–160 mg, and the duration as approximately 4–8 hours. [1] He describes FLEA as causing entactogenic and open MDMA-like effects, easing communication, and increasing appreciation of the senses. [1] Shulgin explained the reasoning for naming the compound "FLEA" in PiHKAL. [1]

Contents

Legality

United Kingdom

This substance is a Class A drug in the Drugs controlled by the UK Misuse of Drugs Act. [2]

See also

References

  1. 1 2 3 4 Shulgin A, Shulgin A (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN   0-9630096-0-5. OCLC   25627628.
  2. "UK Misuse of Drugs act 2001 Amendment summary". Isomer Design. Archived from the original on 22 October 2017. Retrieved 12 March 2014.